Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
HIV Integrase Inhibitory Assay from US Patent US10065950: "Substituted thiazoles as HIV integrase inhibitors"
Assay data:353 Active, 353 Activity ≤ 1 µM, 353 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Reversal of HIV1 Vif mediated A3G degradation in HIV1 infected human H9 cells for 48 hrs by western blotting analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing Myc-tagged pcDNA-APOBEC3G and pcDNA-ubiquitin-His assessed as reduction in Vif-mediated A3G polyubiquitination at 3.5 to 35 nM measured after 48 hrs by Western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing Myc-tagged pcDNA-APOBEC3G and pcDNA-ubiquitin-His assessed as reduction in Vif-mediated A3G polyubiquitination at 10 uM measured after 16 hrs by Western blot analysis
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing eGFP-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10000 nM measured after 48 hrs by flow cytometry
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing eGFP-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10 nM measured after 48 hrs by flow cytometry
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing Myc-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10000 nM measured after 48 hrs by Western blot analysis
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing Myc-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10 nM measured after 48 hrs by Western blot analysis
Inhibition of HIV1 HA-tagged Vif expressed in HEK293T cells co-expressing Myc-tagged pcDNA-APOBEC3G assessed as reduction in Vif-mediated A3G degradation at 10 uM measured after 16 hrs by Western blot analysis
Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral replication by reverse transcriptase assay relative to vehicle-treated control
Assay data:9 Tested
Antagonist activity against HIV-1 GFP-tagged Vif in human HEK293FT cells co-expressing HA-tagged A3G assessed as downregulation of Vif expression expression at 50 uM measured after 16 hrs by immunoblotting method
Assay data:12 Active, 12 Tested
Antagonist activity against HIV-1 GFP-tagged Vif in human HEK293FT cells co-expressing HA-tagged A3G assessed as upregulation of A3G levels at 50 uM measured after 16 hrs by immunoblotting method
Antagonist activity against HIV-1 Vif in human MT4 cells assessed as inhibition of viral infection measured after 16 hrs by cell-based assay
Assay data:2 Tested
Antagonist activity against HIV-1 Vif in human MT4 cells assessed as inhibition of viral infection at 50 uM measured after 16 hrs by cell-based assay
Assay data:88 Tested
Antagonist activity against HIV-1 Vif in human MT4 cells assessed as inhibition of viral infection at 50 and 100 uM measured after 16 hrs by cell-based assay
Antagonist activity against HIV-1 Vif in human H9 cells expressing A3G assessed as inhibition of viral infection measured after 16 hrs by cell-based assay
Assay data:36 Active, 10 Activity ≤ 1 µM, 41 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Antagonist activity against HIV-1 Vif in human CEM cells assessed as inhibition of viral infection
High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G - Summary
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction
Assay data:1501 Active, 89 Activity ≤ 1 µM, 262345 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_Dose_CherryPick_Activity
Assay data:75 Active, 1 Activity ≤ 1 µM, 392 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on